0.693
price up icon0.00%   0.00
after-market 시간 외 거래: .68 -0.013 -1.88%
loading
전일 마감가:
$0.693
열려 있는:
$0.688
하루 거래량:
142.47K
Relative Volume:
0.14
시가총액:
$35.89M
수익:
-
순이익/손실:
$-81.22M
주가수익비율:
-0.2341
EPS:
-2.96
순현금흐름:
$-74.41M
1주 성능:
+1.55%
1개월 성능:
-1.01%
6개월 성능:
-35.23%
1년 성능:
-22.13%
1일 변동 폭
Value
$0.6762
$0.6992
1주일 범위
Value
$0.655
$0.7025
52주 변동 폭
Value
$0.62
$1.70

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name
명칭
Xilio Therapeutics Inc
Name
전화
617-833-1027
Name
주소
828 WINTER STREET, WALTHAM
Name
직원
73
Name
트위터
Name
다음 수익 날짜
2024-11-09
Name
최신 SEC 제출 서류
Name
XLO's Discussions on Twitter

XLO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
XLO
Xilio Therapeutics Inc
0.693 35.89M 0 -81.22M -74.41M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-12-21 개시 Chardan Capital Markets Buy
2022-01-10 개시 H.C. Wainwright Buy
2021-11-16 개시 Cowen Outperform
2021-11-16 개시 Guggenheim Buy
2021-11-16 개시 Morgan Stanley Overweight
2021-11-16 개시 Raymond James Outperform
모두보기

Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스

pulisher
Jun 18, 2025

Xilio Therapeutics Executives Increase Holdings - TradingView

Jun 18, 2025
pulisher
Jun 16, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Jun 16, 2025
pulisher
Jun 12, 2025

Xilio Therapeutics Expands Authorized Shares at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Xilio Therapeutics Appoints Akintunde Bello to Board of Directors - citybiz

Jun 11, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics expands board, elects new director - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Expands Board with New Director - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Leadership Experience 2025: Starbucks Rallies 14,000 North America Coffeehouse Leaders to Accelerate its 'Back to Starbucks' Strategy - The Globe and Mail

Jun 10, 2025
pulisher
Jun 08, 2025

Uranium Royalty Corp. Announces U.S.$30 Million Bought Deal Financing - The Globe and Mail

Jun 08, 2025
pulisher
Jun 06, 2025

Musk-Trump Messy Breakup Wipes Out $150B in TSLA Stock: What's Next? - The Globe and Mail

Jun 06, 2025
pulisher
Jun 05, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 04, 2025

Market Analysis: June 4th, 2025 - The Globe and Mail

Jun 04, 2025
pulisher
Jun 03, 2025

International Resources Holding Enters into Agreement to Acquire Majority Interest in Alphamin Resources Corp. from Tremont Master Holdings - The Globe and Mail

Jun 03, 2025
pulisher
Jun 03, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Xilio Therapeutics Inc (NASDAQ: XLO) Is Down -26.69% Year-To-Date, But Analysts Find Room For A Price Rally - Stocksregister

Jun 03, 2025
pulisher
Jun 03, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider

Jun 03, 2025
pulisher
Jun 03, 2025

Xilio Therapeutics announces public offering of warrants By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics tumbles after $50 mln equity offering - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics (XLO) Launches Public Offering of Warrants | - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics announces pricing of $50 million public offering - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics (XLO) Launches Public Offering of Warrants | XLO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics (XLO) Stock Dips Following Public Offering Announcement - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics Secures $150M Potential Funding Through Strategic Warrant Offering for Cancer Therapies - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics Announces Proposed Public Offering - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics (XLO) Launches Public Offering for Warrants | - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

SEC Form 424B5 filed by Xilio Therapeutics Inc. - Quantisnow

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics drops on equity raise plans - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics Presents Phase 2 Trial Data Update - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics announces public offering of warrants - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Xilio Therapeutics (XLO) Reveals Positive Phase 2 Trial Data for Cancer Treatment | XLO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire

Jun 01, 2025
pulisher
May 31, 2025

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer - Nasdaq

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - The Manila Times

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer - marketscreener.com

May 31, 2025
pulisher
May 31, 2025

Breakthrough: New Immunotherapy Achieves 26% Response Rate in Hard-to-Treat Colorectal Cancer Patients - Stock Titan

May 31, 2025
pulisher
May 30, 2025

Xilio Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 30, 2025
pulisher
May 30, 2025

Thinking Of Buying Xilio Therapeutics Inc (NASDAQ: XLO) Stock? Here Is What You Should Know - Stocksregister

May 30, 2025
pulisher
May 25, 2025

Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World

May 25, 2025

Xilio Therapeutics Inc (XLO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Xilio Therapeutics Inc 주식 (XLO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Shannon James Samuel
Director
Jun 17 '25
Buy
0.69
25,000
17,215
70,000
Russo Rene
PRESIDENT AND CEO
Jun 16 '25
Buy
0.68
36,289
24,680
281,172
Frankenfield Christopher James
Chief Financial Officer
Jan 02 '25
Sale
0.98
6,954
6,841
12,421
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
Jan 02 '25
Sale
0.98
1,803
1,774
3,197
GILEAD SCIENCES, INC.
10% Owner
Dec 18 '24
Buy
1.04
1,759,978
1,830,377
9,105,451
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):